Key Drivers
- Large cash reserve
- Negative free cashflow
- Improving margins
AIAI Summary
Recursion should be re‑rated as a TechBio platform with meaningful near‑term optionality from nondilutive partnerships (notably Roche) rather than a pure pre‑revenue biotech, so investors should shift focus to the cadence and convertibility of partnership milestone revenue and whether management hits its >$100M 2026 partnership target. Key risk/opportunity: if milestone inflows prove repeatable and 2026 expense guidance reduces burn, the stock has asymmetric upside; if revenues remain lumpy or partnerships stall, dilution or value impairment is likely before GAAP profitability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Large cash reserve
- •Negative free cashflow
- •Improving margins
RXRX has a strong cash position ($747.9M) and low leverage with improving quarterly margins but remains unprofitable with heavy R&D/opex-driven negative operating and free cash flow, implying reliance on cash runway or financing.
Price Behavior
Key Price Behavior Insights:
- •Below last month avg
- •Intraday bounces
- •Breakdown risk
Stock is in a short-term downtrend, closing at $3.25 below the last month average (~$3.49) with intraday bounces in the $3.29–$3.46 area but at risk of breaking support around $3.25–$3.29 unless it reclaims $3.49 and then $3.77.
Closed at the last-month sample low $3.25 on 2026-03-20, signaling near-term weakness
Sentiment & News
Key News Insights:
- •Cash runway extended
- •Roche milestone
- •AI validation push
Recursion beat Q4 expectations, extended cash runway into 2028 on a Roche milestone, and is aggressively pitching its AI-driven TechBio strategy amid modest stock moves and investor outreach.
The milestone-funded runway lowers near-term financing risk, but demonstrating concrete AI-derived R&D value will be key to sustaining investor confidence and share appreciation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings